PolyPid Ltd. (PYPD) Discusses the Science and Business Case for D-PLEX100 in Tackling Surgical Site Infections Transcript

Company Overview - PolyPid is a company with a market capitalization of $78 million [1] - The company has developed a product named D-PLEX100, which will be discussed in detail during the webinar [1] Analyst Insights - The analyst covering PolyPid has a buy rating on the stock [2] - The 12-month price target for PolyPid is set at $9 per share [2]